Q2 FY2026 · ended Jun 30, 2026 · Revenue $161.28M, +34.6% YoY · Filed Aug 6, 2026
Starling Oncology, Inc. (STLN) files with the SEC under industry code 8011, Services-Offices & Clinics of Doctors of Medicine. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $161.3 million and a net loss of $9.8 million. Free cash flow was $11.0 million. As of Jun 30, 2026 it held $41.1 million in cash and investments and $104.5 million in total debt.
Company profile
- Industry
- Services-Offices & Clinics of Doctors of Medicine (SIC 8011)
- Listed as
- STLN (Nasdaq), DFPH (OTC), STLNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1799191
- Former names
- Oncology Institute, Inc. (until Aug 3, 2026); DFP HEALTHCARE ACQUISITIONS CORP. (until Nov 12, 2021)
Other Services-Offices & Clinics of Doctors of Medicine companies
- Hims & Hers Health, Inc. HIMS
- Teladoc Health, Inc. TDOC
- SBC Medical Group Holdings Inc SBC
- Auna S.A. AUNA
- Airsculpt Technologies, Inc. AIRS
- LifeMD, Inc. LFMD
- Westin Acquisition Corp WSTN
- Basel Medical Group Ltd BMGL
All 12 Services-Offices & Clinics of Doctors of Medicine companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $161.3M | $147.4M | $142.0M | $136.6M | $119.8M |
| Operating income | -$4.6M | -$6.5M | -$6.9M | -$8.1M | -$11.2M |
| Net income | -$9.8M | -$2.5M | -$7.5M | -$16.5M | -$17.0M |
| Diluted EPS | -$0.08 | -$0.02 | -$0.06 | -$0.14 | -$0.15 |
| Operating cash flow | $11.9M | -$2.2M | $3.2M | -$12.6M | -$10.2M |
| Free cash flow | $11.0M | -$3.3M | $2.2M | -$13.2M | -$11.4M |
| Total assets | $178.2M | $168.2M | $164.7M | $163.6M | $159.8M |
| Total liabilities | $203.1M | $184.5M | $180.4M | $175.9M | $168.8M |
| Stockholders' equity | -$24.9M | -$16.3M | -$15.7M | -$12.3M | -$9.0M |
| Cash and investments | $41.1M | $30.3M | $33.6M | $27.7M | $30.3M |
| Total debt | $104.5M | $104.9M | $103.8M | $103.6M | $103.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Aug 21, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 3, 2026 | Jul 28, 2026 |
All 544 Starling Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.